Publications

2021

Pan PC, Pisapia DJ, Ramakrishna R, Schwartz TH, Pannullo SC, Knisely JP, et al. Outcomes following upfront radiation versus monitoring in atypical meningiomas: 16-year experience at a tertiary medical center. Neurooncol Adv. 2021;3(1):vdab094.
Rendeiro AF, Casano J, Vorkas CK, Singh H, Morales A, DeSimone RA, et al. Profiling of immune dysfunction in COVID-19 patients allows early prediction of disease progression. Life Sci Alliance. 2021;4(2).
Patel A, Hoda SA, Swistel AJ. Mammary myofibroblastoma in a male: A classic case. Breast J. 2021;27(2):181-182.
Sohani AR, Maurer MJ, Giri S, Pitcher B, Chadburn A, Said JW, et al. Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy. Am J Surg Pathol. 2021;45(3):384-393.
Jurgens EM, Ketas TJ, Zhao Z, Satlin MJ, Small CB, Sukhu A, et al. Serologic response to mRNA COVID-19 vaccination in lymphoma patients. Am J Hematol. 2021;96(11):E410-E413.
Gaebler C, Wang Z, Lorenzi JC, Muecksch F, Finkin S, Tokuyama M, et al. Evolution of antibody immunity to SARS-CoV-2. Nature. 2021;591(7851):639-644.
Nickeleit V, Singh HK, Dadhania D, Cornea V, El-Husseini A, Castellanos A, et al. The 2018 Banff Working Group classification of definitive polyomavirus nephropathy: A multicenter validation study in the modern era. Am J Transplant. 2021;21(2):669-680.
Su H, Yang F, Fu R, Li X, French R, Mose E, et al. Cancer cells escape autophagy inhibition via NRF2-induced macropinocytosis. Cancer Cell. 2021;39(5):678-693.e11.
Fangusaro J, Onar-Thomas A, Poussaint TY, Wu S, Ligon AH, Lindeman N, et al. A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study. Neuro Oncol. 2021;23(10):1777-1788.
Padilla O, Tam W, Geyer JT. T-cell neoplasms in the spleen. Semin Diagn Pathol. 2021;38(2):135-143.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700